Key result
Concurrent administration of rifampicin and warfarin prevented the achievement of a therapeutic INR despite escalating warfarin doses up to 10 mg daily, requiring discontinuation of rifampicin to reach the target INR.
Why the study?
Does concurrent rifampicin therapy prevent achieving target INR in patients on warfarin?
Population
60-year-old man with a history of deep vein thrombosis
Comparison
Concurrent warfarin and rifampicin therapy vs Warfarin therapy alone
Design
Case_report
Follow-up
over 2 months
Authors
Loading...
Case report of refractory INR control with rifampicin coadministration warrants vigilant monitoring; leaves open optimal dosing protocols.
Case Report (n=1)
No
Does concurrent rifampicin therapy prevent achieving target INR in patients on warfarin?
Concurrent use of rifampicin and warfarin makes achieving therapeutic INR extremely difficult due to CYP450 induction, necessitating the avoidance of rifampicin in these patients.
Subhash Chandra Jha (2015) conducted a case report in Deep vein thrombosis and tuberculosis (n=1). Concurrent warfarin and rifampicin vs. Warfarin alone (after stopping rifampicin) was evaluated on Achievement of target INR (2-3). Concurrent administration of rifampicin and warfarin prevented the achievement of a therapeutic INR despite escalating warfarin doses up to 10 mg daily, requiring discontinuation of rifampicin to reach the target INR.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: